In Focus: Apply Expert-Driven Care Coordination Strategies in Retinal Disease Management

Track 1 - Emerging Clinical Updates and Treatment Management Strategies in Retinal Diseases for Managed Care Professionals
Track 2 - Case-Based Application of Health Plan Best Practices for the Management of Retinal Diseases

Each track is certified for 0.75 hours/credits. Learners must complete both webinars to receive the full 1.5 hours/credits.

Learn About:

• Payer best practice strategies
• Recent AMD and DR/DME clinical updates for use in managed care strategies and treatment protocols
• Patient perspectives on care access, quality, and outcomes in AMD, DR/DME and retinal vein occlusion (RVO)
• New evidence-based approaches in age-related macular degeneration (AMD) and diabetic retinopathy and diabetic macular edema (DR/DME)

Expert Faculty Presenters:

Track 1 - Emerging Clinical Updates and Treatment Management Strategies in Retinal Diseases for Managed Care Professionals Steven Kheloussi, PharmD, MBA, FAMCP Principal Consultant Kheloussi Consulting, LLC Click here for biography Ferhina Ali, MD, MPH, FASRS Vitreoretinal Physician and Surgeon Westchester Medical Center/Advanced Physician Services Assistant Professor of Ophthalmology New York Medical College Click here for biography Jeremy Wigginton, MD, MBA, FAAFP Chief Medical Officer Capital Blue Cross Click here for biography Track 2 - Case-Based Application of Health Plan Best Practices for the Management of Retinal Diseases Steven Kheloussi, PharmD, MBA, FAMCP Principal Consultant Kheloussi Consulting, LLC Click here for biography Mark Barakat, MD Director of Research Retina Macula Institute of Arizona Medical Director Spectra Eye Institute Click here for biography Michael Shannon, MD Endocrinologist Summit Pacific Medical Center Medical Director Ventegra Click here for biography

Target Audience
This activity is designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.

Statement of Need/Program Overview
While the choice of treatment for retinal diseases is largely based on the experience and preference of the treating retinal specialist and patient preferences, payers are key stakeholders in impacting treatment selection through formulary placement, step therapy, and site-of-care policies which can affect member access. These webcasts will educate on how to apply health plan best practices to improve retinal disease management.

Educational Objectives

Track 1:
After completing this activity, the participant should be better able to:

• Evaluate new evidence-based approaches aimed at improving patient outcomes in AMD and DR/DME through timely interventions
• Recommend recent AMD and DR/DME clinical updates for use in managed care strategies and treatment protocols for improved care delivery

• Analyze patient perspectives on care access, quality, and outcomes in AMD, DR/DME, and retinal vein occlusion (RVO)
• Outline the successful implementation of payer best practice strategies in AMD, DR/DME, and RVO to improve patient outcomes

Accreditation Information

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Impact Education, LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Medical Education Resources designates these live activities for a maximum of 1.5 AMA PRA Category 1 Credits™ (0.75 AMA PRA Category 1 Credits™ per track). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Medical Education Resources designates these continuing education activities for a total of 1.5 contact hours (0.15 CEUs) (0.75 contact hours (0.075 CEUs) per track) of the Accreditation Council for Pharmacy Education.

Please note: Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Continuing Nursing Education
Medical Education Resources designates these live activities for a maximum of 1.5 ANCC nursing contact hours (0.75 ANCC nursing contact hours per track). Nurses will be awarded contact hours upon successful completion of the activity.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 1.5 contact hours total (0.75 contact hours per track).

Disclosure of Financial Relationships
Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies all relevant financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported relevant financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in health care and not the business interest of an ineligible company. The authors reported the following financial relationships with ineligible companies whose products or services may be mentioned in this activity:

The content managers reported the following financial relationships with ineligible companies whose products or services may be mentioned in this activity:

DISCLAIMER
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Impact Education, LLC, and/or Regeneron Pharmaceuticals, Inc. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

FEE INFORMATION
There is no fee for this educational activity.